Drug intelligence / Profile preview

SMART-201

Development stage: Preclinical
Lead developer: Smart Immune
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

SMART-201 is a universal CAR-T cell therapy drug candidate developed by Smart Immune. It is designed as a gene transference and T lymphocyte replacement therapy, with its primary therapeutic areas being neoplasms and hemic and lymphatic diseases, specifically targeting hematologic neoplasms. As of March 2025, the highest reported development phase for SMART-201 is preclinical. The drug aims to provide an innovative approach to treating blood cancers by leveraging engineered T cells for immune system modulation[1].

Beyond the preview

Go deeper on SMART-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SMART-201.

Explore the full profile